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was lower in C-1 (geometric mean [GM] 13.4 L/h/m2) than 
expected (26.4 L/h/m2), but similar in C-2 (23.5 L/h/m2) 
and C-3 (27.9 L/h/m2). CL/BSA in C-4 was 18.1 L/h/m2. 
Compared with C-2, CL/BSA increased 19% in C-3 (GM 
ratio 1.19; 90% CI 0.74–1.91), but decreased 23% in C-4 
(0.77; 0.39–1.53). Cabazitaxel free fraction was unaltered. 
No significant correlation was found between grade 3–4 
toxicities and pharmacokinetic parameters.
Conclusions  Mild–moderate HI did not cause substantial 
decline in cabazitaxel clearance. Cabazitaxel dose reduc-
tions in patients with mild–moderate HI, and a contrain-
dication in patients with severe HI, are justified based on 
safety data.
Keywords Cabazitaxel · Hepatic impairment · Maximum 
tolerated dose · Pharmacokinetics · Phase I
Abstract 
Purpose Cabazitaxel has not been studied in patients 
with hepatic impairment (HI). This phase I study assessed 
cabazitaxel safety and pharmacokinetics in patients with 
HI.
Methods Patients with advanced, non-hematologic cancer, 
and normal hepatic function (Cohort 1: C-1), or mild (C-2), 
moderate (C-3), severe (C-4) HI received cabazitaxel start-
ing doses of 25, 20, 10, and 10 mg/m2, respectively. Doses 
were escalated in patients with HI based on Cycle 1 dose-
limiting toxicities (DLTs). Adverse events and the cabazi-
taxel pharmacokinetic profile were assessed.
Results In C-2, three patients receiving cabazitaxel 25 mg/
m2 experienced DLTs; maximum tolerated dose (MTD) 
was 20 mg/m2. In C-3, two patients receiving 20 mg/m2 
experienced DLTs; MTD was 15 mg/m2. C-4 was discon-
tinued early due to DLTs. The most frequent cabazitaxel-
related, grade 3–4 toxicity was neutropenia (42%). Cabazi-
taxel clearance normalized to body surface area (CL/BSA) 
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Introduction
Cabazitaxel, a second-generation semisynthetic taxane, 
has demonstrated activity in the second-line treatment of 
metastatic castration-resistant prostate cancer (mCRPC) 
after progression on docetaxel-based treatment [1]. Cabazi-
taxel is approved in combination with prednisone or pred-
nisolone for mCRPC [1–3]. Similar to the first-generation 
taxanes, paclitaxel and docetaxel, cabazitaxel is primar-
ily metabolized by the liver, mainly by cytochrome P450 
CYP3A4/5 isoenzyme and, to a lesser extent, CYP2C8, and 
is excreted in the bile via the feces [2, 4, 5].
Hepatic impairment may have an unpredictable impact 
on the pharmacokinetics (PK) of chemotherapies metabo-
lized by the liver, and low serum albumin levels associated 
with hepatic impairment can result in an increased fraction 
of free drug leading to increased toxicity [6–9]. Based on 
this, clinical trials have generally excluded patients with 
significant hepatic impairment. For many chemotherapy 
agents, there are no specific data to guide chemotherapy 
dosing in patients with hepatic impairment and current rec-
ommendations remain empiric.
As previous studies of cabazitaxel in solid tumors 
excluded patients with hepatic impairment, the safety pro-
file of cabazitaxel in this subgroup has not been established 
[1, 10]. Here, we present the results of a study that exam-
ined the PK and safety profile of cabazitaxel in patients 
with varying degrees of hepatic impairment.
Materials and methods
Study design
This was an open-label, dose-escalation, multicenter, phase 
I study (NCT01140607) of cabazitaxel in patients with 
non-hematologic cancers and varying degrees of hepatic 
function. This study was designed to evaluate the maximum 
tolerated dose (MTD) and safety, and assess the PK prop-
erties and relationship between PK and safety parameters, 
of cabazitaxel in patients with varying degrees of hepatic 
impairment. A similar design was employed in the study of 
irinotecan in patients with hepatic dysfunction [11]. This 
study was approved by ethics committees/review boards at 
all participating institutions, and all patients provided writ-
ten informed consent prior to participation. According to 
the cabazitaxel dose-escalation schedule and dose-escala-
tion decision rules defined in the protocol, which specified 
different starting dose levels for each cohort and were based 
on the number of dose-limiting toxicities (DLTs) observed 
at the different dose levels, a total of 39–75 patients were 
expected to be enrolled. This sample size would ensure 
that at least six patients would be enrolled in Cohort 1, 12 
patients at MTD in Cohort 2, six patients at MTD in Cohort 
3, and six patients at MTD in Cohort 4, in order to evaluate 
the safety and PK profile of cabazitaxel.
Patients
Eligible patients were aged ≥18 years with a life expectancy 
of >3 months, diagnosed with metastatic or locally advanced 
non-hematologic cancer for which no effective curative ther-
apy was available, had refractory or progressive disease fol-
lowing standard therapies, and had normal hepatic function 
or chronic hepatic impairment. Patients were enrolled into 
one of four cohorts based on their degree of hepatic function, 
defined using National Cancer Institute (NCI) criteria [12]. 
Cohort 1 had normal hepatic function, defined as total bili-
rubin and aspartate aminotransferase (AST) ≤ institutional 
upper limit of normal (ULN); Cohort 2 had mild hepatic 
impairment, defined as total bilirubin >1.0 to ≤1.5 × ULN 
or AST >1.5 × ULN; Cohort 3 had moderate hepatic impair-
ment, defined as total bilirubin >1.5 to ≤3.0 × ULN; and 
Cohort 4 had severe hepatic impairment, defined as total bili-
rubin >3.0 to 10.0 × ULN. Stable liver function or dysfunc-
tion was required. Key exclusion criteria included Eastern 
Cooperative Oncology Group (ECOG) performance status 
>2, prior bone marrow transplant or cabazitaxel, known brain 
metastases, history of Gilbert’s syndrome or grade ≥3 hyper-
sensitivity to taxanes, polysorbate 80 or similar compounds, 
prior anticancer therapy <3 weeks before study initiation, 
concurrent or planned participation in another clinical trial, 
expected need for major surgery or radiation therapy during 
the study, other concurrent serious illness, acute or chronic 
medical illness or psychiatric condition that might affect the 
trial results or the patients’ ability to participate. Patients with 
significant laboratory abnormalities requiring further investi-
gation, unresolved significant toxicity from prior therapy, or 
inadequate organ function were also excluded.
Study treatment
Patients received cabazitaxel during a 1-hour intravenous 
(IV) infusion on Day 1 of each 3-week cycle until unac-
ceptable toxicity, disease progression, withdrawal of 
consent, investigator decision, or study cutoff. Different 
starting doses of cabazitaxel were used for each cohort 
based on information from the BEX6702 study [13]. The 
cabazitaxel starting dose (dose level [DL] 0) was based on 
the level of hepatic function: Cohort 1 (normal function) 
received 25 mg/m2, Cohort 2 (mild hepatic impairment) 
received 20 mg/m2, and Cohorts 3 and 4 (moderate or 
severe hepatic impairment) received 10 mg/m2. The start-
ing dose for Cohort 4 was decided by the Study Committee 
based on safety and PK findings in the first three patients 
treated in Cohort 3. Doses were adjusted in Cohorts 2, 3, 
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and 4 based on DLTs observed in Cycle 1. In Cohort 2, 
doses were adjusted to 15 mg/m2 (DL –1) or 25 mg/m2 
(DL +1), and in Cohorts 3 and 4, doses were adjusted to 
15 mg/m2 (DL +1), 20 mg/m2 (DL +2), or 25 mg/m2 (DL 
+3). If a Cycle 1 DLT was observed in at least two of up 
to six patients at a given dose level, no further dose escala-
tion occurred. If a Cycle 1 DLT occurred in one of the first 
three patients treated at a given dose level, three additional 
patients received that dose. The MTD was the highest dose 
at which none of the first three patients or one of up to six 
total patients experienced a Cycle 1 DLT up to the 25 mg/
m2 dose. Use of granulocyte colony-stimulating factor 
(G-CSF) was not permitted during Cycle 1.
Safety assessments
Safety evaluations included vital signs, physical examina-
tions, ECOG performance status, electrocardiograms, and 
laboratory parameter tests. Adverse events (AEs) were 
assessed according to the NCI Common Terminology 
Criteria for AEs (CTCAE) v4.03 [14] from the time of 
informed consent until ≥30 days after last cabazitaxel dose. 
DLTs were defined as cabazitaxel-related clinical AEs or 
laboratory abnormalities. Liver DLTs included increases 
in bilirubin and/or transaminase levels to three times the 
baseline value. Other DLTs included grade 3–4 non-hema-
tologic AEs (excluding grade 3 fatigue, anorexia, fever 
without infection, inadequately treated nausea, vomiting, 
mucositis or stomatitis; transaminase or bilirubin eleva-
tions returning to baseline by next treatment cycle [Cohort 
1]; hypersensitivity reaction in the absence of required pre-
medication; peripheral neuropathy returning to grade 2 by 
next treatment cycle) and hematologic toxicity defined as 
febrile neutropenia, grade 4 neutropenia lasting more than 
seven days, or grade 4 thrombocytopenia.
Pharmacokinetic assessments
Heparinized blood samples were collected from all 
patients in Cycle 1, on Day 1 immediately prior to the start 
of infusion, 5 min before the end of infusion, and then at 
5, 15, and 30 min and 1, 2, 3, 5, 7, and 10 h after the end 
of infusion. Samples were also collected on Days 2, 3, 4, 
5, 8, and 10 after cabazitaxel infusion. Cabazitaxel plasma 
concentrations were analyzed using a validated liquid 
chromatography with tandem mass spectrometry method 
(LC-MS/MS; lower limit of quantitation [LLOQ] = 1 ng/
mL). Cabazitaxel PK parameters were calculated using 
non-compartmental analysis with validated software 
(PKDMS Version 2.0 with WinNonlin Professional, Ver-
sion 5.2.1, Pharsight). PK parameters included maximum 
observed concentration (Cmax), area under the concentra-
tion versus time curve extrapolated to infinity (AUCinf), 
area under the concentration versus time curve calculated 
using the trapezoidal method from time 0 to real-time tlast 
(AUClast), terminal half-life (t1/2z), total body clearance 
(CL), and volume of distribution at steady state (Vss). CL 
and Vss were normalized to body surface area (BSA; CL/
BSA, Vss/BSA). Effect of hepatic impairment on cabazi-
taxel PK parameters (CL/BSA and dose-normalized expo-
sure parameters [AUC/dose]) was evaluated using linear 
mixed-effect modelling with degree of hepatic impair-
ment as the fixed effect. Additional plasma samples were 
collected 5 min before, 3 h after and 24 h after the start 
of infusion to determine the cabazitaxel free fraction after 
equilibrium dialysis in buffer using a validated LC-MS/
MS method with a LLOQ of 0.1 ng/mL. Cabazitaxel free 
fraction was estimated using a linear mixed-effect model, 
with cohort and dose level as fixed effect and time and 
BSA as continuous variable and patient as random effect.
Results
Baseline patient characteristics
Of 77 patients screened, 43 were enrolled including six 
patients in Cohort 1 (normal hepatic function), 18 in 
Cohort 2 (mild impairment), 12 in Cohort 3 (moderate 
impairment), and seven in Cohort 4 (severe impairment) 
(Table 1). The remaining patients (n = 34) were consid-
ered non-eligible based on inclusion and/or exclusion 
criteria. Overall, approximately half of the patients were 
male, median age was 60 years (range 18–79 years), and 
most patients (81%) had an ECOG performance status of 
1. Patients had various primary tumors with colon and liver 
the most frequent (19% each). At study entry, most patients 
had metastatic disease (91%), some had locally advanced 
disease (7%), and a minority had locoregional recurrence 
(2%). Median time from cancer diagnosis to first cabazi-
taxel dose was 2.93 years (range 0.5–17.9 years), and 
median time from last relapse/progression to first cabazi-
taxel dose was 1.08 months (range 0.2–24.2 months). 
Approximately two-thirds of patients had received three or 
more prior anticancer regimens.
Treatment
The cabazitaxel doses administered in each cohort were 
as follows: Cohort 1 (normal hepatic function), 25 mg/m2; 
Cohort 2 (mild impairment), 20 and 25 mg/m2; and Cohorts 
3 (moderate impairment) and 4 (severe impairment), 10, 15, 
and 20 mg/m2 (Table 1). Patients received a median of two 
cycles of cabazitaxel (range 1–31 cycles) (Table 2). The 
median number of cycles and relative dose intensity ver-
sus planned dose was similar across cohorts. The median 
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duration of treatment was 6 weeks (range 3–107 weeks). 
All patients had discontinued study treatment at study cut-
off, except for one patient in Cohort 2 (20 mg/m2) who had 
received 31 cycles. Primary reasons for cabazitaxel discon-
tinuation included disease progression (65%) and toxicity/
AEs (21%) (Table 2).
Safety data
Of the 43 treated patients, 38 were evaluable for DLTs 
with five excluded due to concomitant G-CSF administra-
tion during Cycle 1 in the absence of a DLT. In Cycle 1, 
13 patients (34%) across all cohorts experienced a DLT 
(Table 3). Hematologic and non-hematologic DLTs were 
each reported in eight patients (21%) with three patients 
experiencing both. No liver-related DLTs were reported. In 
Cohort 2 (mild hepatic impairment), three of five patients 
receiving 25 mg/m2 experienced DLTs (grade 4 febrile 
neutropenia, grade 3 hypophosphatemia, and grade 4 neu-
tropenia without fever), and the MTD was established as 
20 mg/m2. In Cohort 3 (moderate impairment), the first 
two patients treated at 20 mg/m2 experienced DLTs (grade 
4 neutropenic sepsis, and grade 3 febrile neutropenia and 
stoma site infection), and the MTD was established as 
15 mg/m2. In Cohort 4 (severe impairment), the MTD 
was not established because no patient treated with 10 or 
15 mg/m2 experienced DLTs during Cycle 1 and treat-
ment was discontinued early for this cohort because the 
first patient treated at 20 mg/m2 experienced DLTs and 
subsequently died from a combination of septic shock, 
tumor lysis syndrome and acute respiratory failure in the 
context of acute renal failure and disease progression. 
Based on this outcome, patient accrual into Cohort 4 was 
discontinued.
AEs were assessed in all patients (Table 3). The most 
frequent treatment-emergent AEs (TEAEs) of any grade 
(in >25% of patients overall), regardless of causality, 
were fatigue (54%), neutropenia (42%), diarrhea (40%), 
nausea (40%), anemia (37%), vomiting (35%), abdomi-
nal pain (28%), and peripheral edema (26%). The most 
frequent TEAEs were observed in all cohorts, except 
for vomiting which was not reported in Cohort 1. The 
most frequent grade 3–4 TEAEs (in >3 patients over-
all), regardless of causality, were neutropenia (42%), 
anemia (23%), febrile neutropenia (16%), abdominal 
pain (14%), leukopenia (9%), and dehydration (9%). Six 
patients (14%) presented with a TEAE (of any causality) 
related to hepatobiliary disorders: one patient in Cohort 
2 (mild hepatic impairment) and five patients in Cohort 
3 (moderate impairment). Neutropenia was the most fre-
quent grade 3–4 treatment-related TEAE (Table 3). Anal-
ysis of AEs did not reveal any trends related to hepatic 
impairment.
Pharmacokinetics
Of 43 patients, 38 were eligible for PK assessment 
(Table 4). Four patients were excluded because of PK 
deviations and one patient because of ineligibility for any 
defined cohort in the study. In addition, two patients from 
Cohort 3 receiving cabazitaxel 10 mg/m2 were excluded 
from PK analysis because they displayed aberrant PK 
behaviors, including a very low Cmax and a mean CL/
BSA (517 L/h/m2) that was approximately 20-fold higher 
than other patients in Cohort 3 (30.5 L/h/m2 for patients 
receiving cabazitaxel 15 and 20 mg/m2 collectively). The 
CL/BSA estimate for patients in Cohort 1 (normal hepatic 
function; 13.4 L/h/m2) was in the very low range of typi-
cal cabazitaxel clearance shown in a previous population 
PK analysis (26.4 L/h/m2, coefficient of variation: 38.8%; 
n = 170) [15] and other phase I studies assessing cabazi-
taxel PK (28.6 L/h/m2, n = 4 [13]; 27.3 L/h/m2, n = 25 
[16]; 44.7 L/h/m2 n = 21 [17]). Because of this unusu-
ally low cabazitaxel clearance in Cohort 1, meaning-
ful PK comparisons could not be made between patients 
with hepatic impairment and normal hepatic function. As 
a result, comparisons were made using patients with mild 
hepatic impairment. Compared with Cohort 2 (mild hepatic 
impairment), Cohort 3 (moderate impairment) showed a 
19% increase in CL/BSA, associated with a 14% decrease 
in AUClast/dose, whereas Cohort 4 (severe impairment) 
showed a 23% decrease in CL/BSA, associated with a 17% 
increase in AUClast/dose (Table 5; Fig. 1a). A sensitivity 
analysis, which excluded patients with erratic PK profiles, 
showed consistent findings to the main analysis. Compared 
with Cohort 2, Cohort 3 showed a 6% decrease in CL/
BSA (ratio: 0.94; 90% CI 0.64–1.38) and Cohort 4 showed 
a 39% decrease (ratio: 0.61; 90% CI 0.36–1.05). Hepatic 
impairment did not affect the free fraction of cabazi-
taxel (5.6–6.6% across the cohorts); thus, analysis of free 
drug PK led to the same conclusions as for total drug PK 
(Fig. 1b).
Correlation between safety and PK parameters
No significant correlation (p < 0.05) was found between 
grade 3–4 TEAEs or laboratory abnormalities in Cycle 1 
and PK parameters. Study cohort (degree of hepatic func-
tion) was not a statistically significant covariate in any of 
the logistic regression models of PK parameters.
Efficacy
There were no efficacy endpoints in this study, and there-
fore, data were not routinely collected. However, one 
patient with cholangiocarcinoma had stable disease, which 
was maintained at Cycle 32.
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Discussion
This study assessed the safety and PK of cabazitaxel in 
patients with hepatic impairment compared with patients 
who have normal hepatic function. Cabazitaxel is primar-
ily metabolized by the liver, and therefore, it is important 
to assess the effect of hepatic impairment on cabazitaxel 
metabolism. The first-generation taxanes, docetaxel and 
Table 5  Pharmacokinetic parameters: effect of hepatic impairment
AUCinf/dose, area under the plasma concentration–time curve extrapolated to infinity normalized to dose; AUCEXT, extrapolated area under the 
plasma concentration–time curve; AUClast/dose, area under the plasma concentration–time curve from time zero to the time of the last cabazi-
taxel concentration, normalized to dose; CL, clearance; CL/BSA, clearance normalized to body surface area; CI, confidence interval; Cmax/dose, 
maximum observed plasma concentration normalized to dose; t1/2z, apparent terminal half-life; Vss, volume of distribution at steady state; Vss/
BSA, volume of distribution at steady state normalized to body surface area
a n = 14, parameter not calculable for one patient (AUCExt >40%)
b n = 8, patients receiving cabazitaxel 10 mg/m2 and displaying aberrant PK behaviors (very low Cmax) were excluded from the statistical analy-
sis and parameter not calculable for one patient (AUCExt > 40%)
c n = 3, parameter not calculable for three patients (AUCExt > 40%)
d n = 9, patients receiving cabazitaxel 10 mg/m2 and displaying aberrant PK behaviors (very low Cmax) were excluded from the statistical analy-
sis
Parameter Cohort (hepatic function/
impairment)
n Geometric mean  
(90% CI)
Versus cohort 1 (normal 
hepatic function)  
Ratio (90% CI)
Versus cohort 2 (mild 
hepatic impairment)  
Ratio (90% CI)
CL, L/h Cohort 1 (normal) 6 23.00 (14.73, 35.92) 1.00 –
Cohort 2 (mild)a 14 42.54 (31.92, 56.71) 1.85 (1.09, 3.14) –
Cohort 3 (moderate)b 8 51.50 (35.12, 75.53) 2.24 (1.24, 4.05) 1.21 (0.75, 1.95)
Cohort 4 (severe)c 3 33.32 (17.91, 62.01) 1.45 (0.67, 3.12) 0.78 (0.40, 1.55)
CL/BSA, L/h/m2 Cohort 1 (normal) 6 13.42 (8.64, 20.83) 1.00 –
Cohort 2 (mild)a 14 23.51 (17.63, 31.35) 1.75 (1.04, 2.96) –
Cohort 3 (moderate)b 8 27.86 (19.03, 40.77) 2.08 (1.16, 3.72) 1.19 (0.74, 1.91)
Cohort 4 (severe)c 3 18.13 (9.73, 33.76) 1.35 (0.63, 2.89) 0.77 (0.39, 1.53)
AUCinf/dose,  
ng*h/mL/mg/m2
Cohort 1 (normal) 6 74.52 (48.01, 115.68) 1.00 –
Cohort 2 (mild)a 14 42.53 (31.89, 56.72) 0.57 (0.34, 0.97) –
Cohort 3 (moderate)b 8 35.91 (24.53, 52.55) 0.48 (0.27, 0.86) 0.84 (0.52, 1.36)
Cohort 4 (severe)c 3 55.17 (29.62, 102.75) 0.74 (0.35, 1.59) 1.30 (0.65, 2.57)
AUClast/dose,  
ng*h/mL/mg/m2
Cohort 1 (normal) 6 64.21 (38.39, 107.40) 1.00 –
Cohort 2 (mild) 15 31.09 (22.46, 43.05) 0.48 (0.26, 0.89) –
Cohort 3 (moderate)d 9 26.6 (17.48, 40.48) 0.41 (0.21, 0.80) 0.86 (0.50, 1.46)
Cohort 4 (severe) 6 36.24 (21.67, 60.62) 0.56 (0.27, 1.17) 1.17 (0.63, 2.14)
Cmax/dose,  
ng/mL/mg/m2
Cohort 1 (normal) 6 21.78 (12.11, 39.18) 1.00 –
Cohort 2 (mild) 15 11.01 (7.60, 15.97) 0.51 (0.25, 1.01) –
Cohort 3 (moderate)d 9 10.08 (6.24, 16.28) 0.46 (0.22, 0.99) 0.92 (0.50, 1.68)
Cohort 4 (severe) 6 8.46 (4.71, 15.23) 0.39 (0.17, 0.89) 0.77 (0.38, 1.54)
t1/2z, h Cohort 1 (normal) 6 71.07 (49.36, 102.31) 1.00 –
Cohort 2 (mild) 15 85.92 (68.55, 107.69) 1.21 (0.79, 1.86) –
Cohort 3 (moderate)d 9 83.64 (62.30, 112.29) 1.18 (0.73, 1.89) 0.97 (0.67, 1.41)
Cohort 4 (severe) 6 102.12 (71.46, 145.92) 1.44 (0.86, 2.39) 1.19 (0.78, 1.81)
Vss, L Cohort 1 (normal) 6 1442.95 (802.87, 2593.34) 1.00 –
Cohort 2 (mild)a 14 3785.17 (2593.95, 5523.44) 2.62 (1.31, 5.27) –
Cohort 3 (moderate)b 8 4005.9 (2421.05, 6628.21) 2.78 (1.27, 6.06) 1.06 (0.56, 1.99)
Cohort 4 (severe)c 3 4981.61 (2201.05, 11,274.82) 3.45 (1.26, 9.46) 1.32 (0.54, 3.24)
Vss/BSA, L/m
2 Cohort 1 (normal) 6 819.68 (464.42, 1446.71) 1.00 –
Cohort 2 (mild)a 14 2093.46 (1443.24, 3036.63) 2.55 (1.30, 5.04) –
Cohort 3 (moderate)b 8 2201.19 (1345.79, 3600.29) 2.69 (1.27, 5.69) 1.05 (0.57, 1.95)
Cohort 4 (severe)c 3 2729.48 (1222.20, 6095.62) 3.33 (1.24, 8.91) 1.30 (0.54, 3.16)
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paclitaxel, are administered at lower doses in patients with 
hepatic impairment because of an increased risk of myelo-
suppression, stomatitis, neutropenia, and treatment-related 
death [4, 5, 18, 19].
In this study, parameters used for patient recruitment 
and for defining hepatic impairment levels were based on 
the NCI criteria [12] and were previously used in a study 
assessing irinotecan in patients with hepatic dysfunction 
[11]. These parameters made patient recruitment challeng-
ing, particularly for severely impaired patients. Using albu-
min levels or Child-Pugh-Turcotte classification scores, 
versus metabolic status, to define hepatic function and 
guide cohort allocation may have been beneficial and may 
have provided a more accurate characterization of hepatic 
function. Potentially, albumin levels could have been cor-
related with PK and safety parameters.
The MTD of cabazitaxel administered by IV infusion 
every 3 weeks in patients with advanced solid tumors was 
determined to be 20 and 15 mg/m2 for patients with mild 
or moderate hepatic impairment, respectively. For patients 
with severe hepatic impairment, treatment in Cohort 4 was 
prematurely discontinued following the death of the first 
patient treated with cabazitaxel 20 mg/m2 from a com-
bination of AEs (including DLTs) and disease progres-
sion; therefore, the MTD in this cohort of patients remains 
undetermined.
The overall safety profile of cabazitaxel was consist-































































12 Normal (n = 6)
Mild (n = 15)
Moderate (n = 9)
Severe (n = 6)
Cabazitaxel clearance normalized to body surface area (CL/BSA)
Individual and mean (and standard deviation) per cohort
Cabazitaxel clearance normalized to body surface area (CL/BSA)
Mean (and standard deviation) per dose and per cohort
Cabazitaxel free fraction




Fig. 1  Pharmacokinetic analysis in the pharmacokinetic population (erratic profiles excluded) of a CL/BSA b cabazitaxel free fraction
350 Cancer Chemother Pharmacol (2017) 79:339–351
1 3
identified. The safety profile of cabazitaxel 20 and 15 mg/
m2 (MTD) in patients with mild or moderate hepatic impair-
ment, respectively, was generally similar to that observed in 
patients with normal hepatic function receiving 25 mg/m2. In 
this study, prophylactic use of G-CSF was not permitted dur-
ing Cycle 1. Prophylactic administration of G-CSF has the 
ability to reduce hematologic toxicity in clinical practice.
As CL/BSA for cabazitaxel in patients with normal 
hepatic function was low compared with historical data 
[13, 15–17], PK data for patients with normal hepatic 
function in this study could not be used in comparisons. 
The reason for these low values is unclear; patients with 
no reason for exclusion showed variability in parameters 
and erratic PK profiles. The number of patients with nor-
mal hepatic function was small (n = 6), which may help 
explain the large variability in cabazitaxel clearance for this 
cohort as several outliers considerably affected the aver-
age values of the cohort and created a substantial shift in 
average CL/BSA. Patients with mild or moderate hepatic 
impairment had CL/BSA values comparable to historical 
data, suggesting no influence of mild or moderate hepatic 
impairment on cabazitaxel PK. There was no evidence 
that moderate versus mild hepatic impairment resulted in 
a substantial decline in cabazitaxel clearance. There was 
no evidence that the lower MTD in patients with mild or 
moderate hepatic impairment, compared with the approved 
25 mg/m2 cabazitaxel dose, were due to higher cabazitaxel 
exposure. Patients with severe hepatic impairment had a 
numerically decreased CL/BSA compared with mildly 
impaired patients, indicating some effect of severe impair-
ment on PK parameters. This numerical increase in cabazi-
taxel exposure may, in part, explain the increased toxicity 
of cabazitaxel observed in this patient cohort. However, 
because of the limitations of a small study and unbalanced 
sample sizes per cohort, this observation should be inter-
preted with caution.
Hepatic impairment had no effect on the cabazitaxel 
unbound fraction with a low free fraction estimated across 
all cohorts (5.6–6.6%). These results are consistent with 
the high binding of cabazitaxel to total plasma proteins 
observed ex vivo and in vitro (89–92%) [2, 15, 17].
Even though cabazitaxel is primarily metabolized by 
CYP3A in the liver, the minimal impact of hepatic impair-
ment on cabazitaxel PK parameters is consistent with a high 
cabazitaxel clearance driven by hepatic blood flow and is 
also consistent with the modest effect that repeated keto-
conazole (a strong CYP3A inhibitor) administration has 
on cabazitaxel clearance; in one study, repeated ketocona-
zole administration resulted in a 20% decrease in cabazi-
taxel clearance [20]. Data from this study support the use 
of cabazitaxel in patients with mild or moderate hepatic 
impairment at reduced doses of 20 and 15 mg/m2, respec-
tively, compared with the approved dose of 25 mg/m2. 
Based on this study and in the absence of appropriate data, 
the use of cabazitaxel is not recommended in patients with 
severe hepatic impairment. Based on PK data, there was no 
evidence of a relationship between safety and PK param-
eters as the lower MTDs could not be justified by higher 
cabazitaxel exposure in patients with mild or moderate 
hepatic impairment. However, dose reductions of cabazi-
taxel in patients with mild or moderate hepatic impairment, 
and contraindication in patients with severe hepatic impair-
ment, are justified based on safety data. A recent phase III 
non-inferiority study (PROSELICA) has demonstrated 
that cabazitaxel administered at a dose of 20 mg/m2 main-
tains at least 50% of the survival benefit observed with the 
approved 25 mg/m2 dose of cabazitaxel versus mitoxantrone 
in the previous phase III TROPIC study [1], in patients with 
mCRPC who have received prior docetaxel treatment [21].
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